Advances in Treatment of Human Epidermal Growth Factor Receptor 2-Positve Gastric Cancer.
10.3881/j.issn.1000.503X.14281
- Author:
Xiao-Qian WU
1
;
Yu-Ping GE
1
;
Xiao-Lei GONG
1
;
Yuan LIU
1
;
Chun-Mei BAI
1
Author Information
1. Department of Medical Oncology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Journal Article
- Keywords:
gastric cancer;
human epidermal growth factor receptor 2;
targeted therapy
- MeSH:
Humans;
Stomach Neoplasms/drug therapy*;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Receptor, ErbB-2;
Trastuzumab/therapeutic use*
- From:
Acta Academiae Medicinae Sinicae
2022;44(5):899-905
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer ranks as the fifth most common malignant tumor worldwide and the fourth leading cause of cancer-related deaths.Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is a special type of gastric adenocarcinoma,the prognosis of which can be improved by trastuzumab plus cytotoxic chemotherapy such as cisplatin and fluorouracil.Pembrolizumab on the basis of Tmabplus chemotherapy can further improve the overall response rate,which has become the first-line standardized therapy against HER2-positive gastric cancer.However,there are still some obstacles such as the innate resistance to Tmab in specific populations.The research on HER2-targeted therapy provides clues for clinical decision-making.This review documents the current neoadjuvant and adjuvant therapies against late-stage HER2-positive gastric cancer,as well as the progress in novel HER2 pathway-targeted drugs.
